Original Medicare provides coverage for IV infusion therapy when a doctor determines it to be medically necessary, both in a clinic setting and at home. Medicare Advantage (Part C) plans need to offer ...

Results were announced from a phase 3 study evaluating an investigational intramuscular (IM) formulation of ibalizumab-uiyk for the treatment of heavily treatment-experienced adults with ...

Credit: Getty Images. The SC formulation is intended to be administered in 10 minutes twice a year. Positive data were announced from a phase 3 trial evaluating an investigational subcutaneous (SC) ...

MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III ...

The advanced technology was added to all ambulances and quick response vehicles in the county beginning February 1st.